Guidelines on “Similar Biologics: Regulatory requirements for Market Authorization in India” will be implemented from 15th September 2012.
The “Guidelines on Similar Biologics” prepared by Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) lay down the regulatory pathway for a similar biologic claiming to be similar to an already authorized reference biologic.
The guidelines address the regulatory pathway regarding manufacturing process and quality aspects for similar biologics.
These guidelines also address the pre-market regulatory requirements including comparability exercise for quality, preclinical and clinical studies and post market regulatory requirements for similar biologics.
For further details visit
https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTU0NA==
Recent Posts
80 Categories, One Product: How to Get Cosmetic Product Categorisation Right in India
The Categorisation Problem Of all the challenges in India’s Cosmetic Import registration process, product categorisation is one of the most underestimated. Under the Cosmetics Rules, 2020, CDSCO..
Authorized Agent for Medical Device Import in India: When You Need One and How to Choose the Right Partner
For foreign Medical Device companies entering India, the authorized agent is not just a compliance checkpoint — it is a strategic regulatory role. The right appointment can support licensing procedu..
How to Obtain CDSCO Approval for Biosimilars in India: Complete 2026 Regulatory Pathway
Why India Demands a Dedicated Biosimilar Strategy India is one of the fastest-growing Biosimilar markets in the world, driven by a large patient population, expanding government healthcare coverage un..
Need Help?
Submit your EnquiryOffice Locations
- Delhi
- Bangalore
- USA
- Singapore